ImmunityBio, Inc. IBRX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s financing cash flow?
- ImmunityBio, Inc. (IBRX) reported financing cash flow of $223.93M in Q1 2026.
- How has ImmunityBio, Inc.'s financing cash flow changed year-over-year?
- ImmunityBio, Inc.'s financing cash flow increased by 22903.1% year-over-year, from -$982K to $223.93M.
- What is the long-term trend for ImmunityBio, Inc.'s financing cash flow?
- Over 4 years (2021 to 2025), ImmunityBio, Inc.'s financing cash flow has grown at a -5.7% compound annual growth rate (CAGR), from $505.44M to $400.24M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.